Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BWAY NASDAQ:LMAT NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$41.07+0.7%$34.60$9.22▼$45.83$2.19B1.171.03 million shs60,921 shsBWAYBrainsway$16.66-0.4%$14.47$4.60▼$17.35$667.87M1.23186,927 shs102,922 shsLMATLeMaitre Vascular$98.37-3.2%$110.09$78.35▼$118.01$2.25B0.6207,964 shs65,600 shsWRBYWarby Parker$27.46-4.6%$23.53$14.96▼$31.00$2.94B1.953.04 million shs617,362 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-3.02%-5.75%+27.63%+18.20%+259.07%BWAYBrainsway-2.56%-0.65%+20.19%+43.30%+284.16%LMATLeMaitre Vascular-5.84%-9.28%-11.32%+15.93%+26.73%WRBYWarby Parker-2.53%+24.37%+38.08%+27.58%+81.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$41.07+0.7%$34.60$9.22▼$45.83$2.19B1.171.03 million shs60,921 shsBWAYBrainsway$16.66-0.4%$14.47$4.60▼$17.35$667.87M1.23186,927 shs102,922 shsLMATLeMaitre Vascular$98.37-3.2%$110.09$78.35▼$118.01$2.25B0.6207,964 shs65,600 shsWRBYWarby Parker$27.46-4.6%$23.53$14.96▼$31.00$2.94B1.953.04 million shs617,362 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-3.02%-5.75%+27.63%+18.20%+259.07%BWAYBrainsway-2.56%-0.65%+20.19%+43.30%+284.16%LMATLeMaitre Vascular-5.84%-9.28%-11.32%+15.93%+26.73%WRBYWarby Parker-2.53%+24.37%+38.08%+27.58%+81.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.64Moderate Buy$46.5013.23% UpsideBWAYBrainsway 3.25Buy$15.00-9.96% DownsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6014.47% UpsideWRBYWarby Parker 2.56Moderate Buy$29.005.62% UpsideCurrent Analyst Ratings BreakdownLatest BWAY, LMAT, WRBY, and AXGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026WRBYWarby Parker UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $27.005/8/2026WRBYWarby Parker Telsey Advisory GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$32.00 ➝ $33.005/7/2026WRBYWarby Parker BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $34.005/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/6/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $120.005/6/2026LMATLeMaitre Vascular Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$118.00 ➝ $127.005/6/2026LMATLeMaitre Vascular Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$94.00 ➝ $104.004/29/2026AXGNAxoGen Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.004/29/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.004/29/2026AXGNAxoGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $50.004/29/2026AXGNAxoGen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M9.70N/AN/A$2.79 per share14.72BWAYBrainsway$52.22M12.77$0.23 per share73.34$1.87 per share8.91LMATLeMaitre Vascular$249.60M9.01$2.65 per share37.19$17.35 per share5.67WRBYWarby Parker$890.57M3.30$0.58 per share46.97$3.48 per share7.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A132.48N/A-13.21%-9.63%-6.26%N/ABWAYBrainsway$7.57M$0.2566.7237.02N/A14.62%11.10%6.97%5/13/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7136.2630.173.0024.35%15.36%9.78%N/AWRBYWarby Parker$1.64M$0.021,373.9462.40N/A0.15%2.32%1.19%N/ALatest BWAY, LMAT, WRBY, and AXGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026BWAYBrainsway$0.05N/AN/AN/A$14.63 millionN/A5/7/2026Q1 2026WRBYWarby Parker$0.11$0.03-$0.08$0.03$239.44 million$242.45 million5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million3/11/2026Q4 2025BWAYBrainsway$0.11$0.14+$0.03$0.14$14.02 million$14.55 million2/25/2026Q4 2025LMATLeMaitre Vascular$0.67$0.68+$0.01$0.68$62.98 million$64.45 million2/24/2026Q4 2025AXGNAxoGen$0.08$0.07-$0.01-$0.28$59.90 million$59.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABWAYBrainswayN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.001.02%+16.05%36.90%14 YearsWRBYWarby ParkerN/AN/AN/AN/AN/ALatest BWAY, LMAT, WRBY, and AXGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.250.89%5/21/20265/21/20266/4/20262/19/2026LMATLeMaitre Vascularquarterly$0.250.94%3/12/20263/12/20263/26/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33BWAYBrainswayN/A3.733.44LMATLeMaitre Vascular0.4214.3212.20WRBYWarby ParkerN/A2.352.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BWAYBrainsway30.11%LMATLeMaitre Vascular84.64%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%BWAYBrainsway19.00%LMATLeMaitre Vascular7.40%WRBYWarby Parker18.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableBWAYBrainsway12040.04 million32.43 millionNot OptionableLMATLeMaitre Vascular49022.85 million21.16 millionOptionableWRBYWarby Parker4,036107.00 million89.10 millionOptionableBWAY, LMAT, WRBY, and AXGN HeadlinesRecent News About These CompaniesVanguard Group Inc. Sells 43,649 Shares of Warby Parker Inc. $WRBYMay 10 at 6:50 AM | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Expected to Rise, Telsey Advisory Group Analyst SaysMay 10 at 5:32 AM | americanbankingnews.comWarby Parker (NYSE:WRBY) Price Target Raised to $34.00May 10 at 5:32 AM | americanbankingnews.comComerica Bank Raises Holdings in Warby Parker Inc. $WRBYMay 10 at 3:41 AM | marketbeat.comA Look At Warby Parker’s Valuation As AI Glasses And Growth Outlook Support A Strong Share Price RunMay 9 at 10:50 PM | finance.yahoo.comWarby Parker Inc. 2026 Q1 - Results - Earnings Call PresentationMay 9 at 7:31 PM | seekingalpha.comWarby Parker (NYSE:WRBY) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPSMay 9 at 5:14 PM | marketbeat.comWarby Parker (WRBY) Q1 2026 Earnings TranscriptMay 9 at 7:49 AM | finance.yahoo.comTelsey Advisory Group Issues Positive Forecast for Warby Parker (NYSE:WRBY) Stock PriceMay 8, 2026 | marketbeat.comWarby Parker Inc. (WRBY) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comWarby Parker (WRBY) Beats Revenue Guidance, Rockets 23%May 7, 2026 | insidermonkey.comWarby Parker (WRBY) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesMay 7, 2026 | zacks.comWarby Parker (NYSE:WRBY) Shares Gap Up Following Analyst UpgradeMay 7, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Expected to Rise, BTIG Research Analyst SaysMay 7, 2026 | marketbeat.comWarby Parker Inc. (WRBY) Surpasses Q1 Earnings and Revenue EstimatesMay 7, 2026 | zacks.comK.J. Harrison & Partners Inc Makes New $1.31 Million Investment in Warby Parker Inc. $WRBYMay 7, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) surprises with Q1 CY2026 sales, stock soarsMay 7, 2026 | msn.comWarby Parker Announces First Quarter 2026 ResultsMay 7, 2026 | businesswire.comWarby Parker (WRBY) Q1 earnings report preview: What to look forMay 7, 2026 | msn.comWarby Parker (WRBY) Gets a Buy from Telsey AdvisoryMay 7, 2026 | theglobeandmail.comWarby Parker Inc (WRBY) Q1 2026 Earnings Report Preview: What To Look ForMay 7, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBWAY, LMAT, WRBY, and AXGN Company DescriptionsAxoGen NASDAQ:AXGN$41.07 +0.28 (+0.68%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Brainsway NASDAQ:BWAY$16.66 -0.07 (-0.42%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.LeMaitre Vascular NASDAQ:LMAT$98.37 -3.27 (-3.22%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Warby Parker NYSE:WRBY$27.46 -1.33 (-4.63%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
